Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C35H68O8P.Na |
| Molecular Weight | 670.8732 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)([O-])=O)OC(=O)CCCCCCCCCCCCCCC
InChI
InChIKey=BMBWFDPPCSTUSZ-MGDILKBHSA-M
InChI=1S/C35H69O8P.Na/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-34(36)41-31-33(32-42-44(38,39)40)43-35(37)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2;/h33H,3-32H2,1-2H3,(H2,38,39,40);/q;+1/p-1/t33-;/m1./s1
1,2-Dipalmitoyl-sn-glycero-3-phosphate monosodium salt (Phosphatidic Acid, DPPA) is a bioactive phospholipid. Dipalmitoylphosphatidic acid (DPPA) is a minor
phospholipid metabolite that is involved in lipid
biosynthesis. DPPA has two palmitic acid moieties
instead of AA and can convert to lyso-PA to increase
Bcl-2 expression in Hela cells but not in B lymphoma
cells. DPPA significantly inhibited tumor
growth, cell proliferation and tumor angiogenesis.
Furthermore, DPPA strongly arrested the G2/M
transition and further inhibited cell cycle progression
in MDA-MB-231 cells. cyclin B1 (CCNB1) was the DPPA target that
regulated cellular proliferation in human TNBC. DPPA, as an anti-cancer drug, inhibited the expression of CCNB1 to arrest the G2/M transition in human TNBC.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Role of phospholipase D2 in anti-apoptotic signaling through increased expressions of Bcl-2 and Bcl-xL. | 2007 Aug 15 |
|
| Determination of liposome-buffer distribution coefficients of charged drugs by capillary electrophoresis frontal analysis. | 2009 Aug |
|
| Catanionic vesicles formed with arginine-based surfactants and 1,2-dipalmitoyl-sn-glycero-3-phosphate monosodium salt. | 2009 May 7 |
Sample Use Guides
Mice: Dipalmitoylphosphatidic acid (DPPA) (3 mg/kg) was
injected every two days for two weeks beginning on
the ninth day after the subcutaneous inoculation of
4T1 cells into the mouse mammary fat pad. At 9
days after the 4T1 cell injection or 7 days after the
MDA-MB-231 cell injection, the mice received an
intravenous tail injection of DPPA (3mg/kg body
weight) .
Route of Administration:
Intravenous
Dipalmitoylphosphatidic acid (DPPA) significantly inhibited the viability of the MDA-MB-231 cells at a concentration greater than 100uM (15% DMSO). Furthermore, the cells were treated with 100uM and 150uM DPPA, and DPPA markedly suppressed cell proliferation in a time-dependent manner.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB22682
Created by
admin on Fri Dec 15 16:05:03 GMT 2023 , Edited by admin on Fri Dec 15 16:05:03 GMT 2023
|
PRIMARY | |||
|
46891879
Created by
admin on Fri Dec 15 16:05:03 GMT 2023 , Edited by admin on Fri Dec 15 16:05:03 GMT 2023
|
PRIMARY | |||
|
169051-60-9
Created by
admin on Fri Dec 15 16:05:03 GMT 2023 , Edited by admin on Fri Dec 15 16:05:03 GMT 2023
|
PRIMARY | |||
|
DTXSID20937581
Created by
admin on Fri Dec 15 16:05:03 GMT 2023 , Edited by admin on Fri Dec 15 16:05:03 GMT 2023
|
PRIMARY | |||
|
PB9252N8GT
Created by
admin on Fri Dec 15 16:05:03 GMT 2023 , Edited by admin on Fri Dec 15 16:05:03 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
